TAM (Treatments and Medicines) NHS HighlandImportant: Therapy notes
For urology use.
Important: Formulation and dosage details
Formulation:
Bladder instillation 12·5mg, 81mg (specialist use only)
Other immunomodulating drugs (Formulary)
What's new / Latest updates
Important: Therapy notes
See NICE guidance TA75.
Important: Formulation and dosage details
Formulation:
Injection pre-filled syringe (alfa-2a (rbe); Roferon-A®) 3 million units/0·5mL, 4·5 million units/0·5mL, 6 million units/0·5mL, 9 million units/0·5mL (specialist use only)
Important: Therapy notes
MHRA advice: Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19) (May 2020) (www.gov.uk)
MHRA advice: Lenalidomide (Revlimid): risk of serious hepatic adverse drug reactions (December 2014) (www.gov.uk)
MHRA advice: Lenalidomide (Revlimid): update on risk of second primary malignancy (December 2014) (www.gov.uk)
MHRA advice: Lenalidomide: risk of thrombosis and thromboembolism (December 2014) (www.gov.uk)
Risk minimisation materials
Important: Therapy notes
Important: Formulation and dosage details
Formulation:
Solution for injection pre-filled syringe (alfa-2a; Pegasys®) 180 micrograms (specialist use only)
Important: Therapy notes
MHRA advice: Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19) (May 2020) (www.gov.uk).
MHRA advice: Pomalidomide (Imnovid): risk of hepatitis B reactivation (May 2016) (www.gov.uk).
MHRA advice: Pomalidomide (Imnovid): risks of cardiac failure, interstitial lung disease and hepatotoxicity (May 2015) (www.gov.uk).
Risk minimisation materials
Important: Formulation and dosage details
Formulation:
Capsules 1mg, 2mg, 3mg, 4mg (specialist use only)
Dosage:
See SMC advice 972/14.
Important: Therapy notes
MHRA advice: Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19) (May 2020) (www.gov.uk).
MHRA advice: Thalidomide: reduced starting dose in patients older than age 75 years (December 2015) (www.gov.uk).
Risk minimisation materials
Important: Formulation and dosage details
Formulation:
Capsules (Thalidomide Celgene®) 50mg (specialist use only)
Dosage:
See SMC advice 525/08.